DDInter576 DDInter1631
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Disulfiram {u} (Compound) treats {v} (Disease) alcohol dependence
Disulfiram {u} (Compound) binds {v} (Gene) DBH
Disulfiram {u} (Compound) upregulates {v} (Gene) FHL2
Disulfiram {u} (Compound) is included by {v} (Pharmacologic Class) Acetyl Aldehyde Dehydrogenase Inhibitors
Disulfiram {u} (Compound) downregulates {v} (Gene) NR2F6
Disulfiram {u} (Compound) causes {v} (Side Effect) Neuropathy
Disulfiram (Compound) treats alcohol dependence (Disease)
Disulfiram (Compound) binds DBH (Gene)
Disulfiram (Compound) upregulates FHL2 (Gene)
Disulfiram (Compound) is included by Acetyl Aldehyde Dehydrogenase Inhibitors (Pharmacologic Class)
Disulfiram (Compound) downregulates NR2F6 (Gene)
Disulfiram (Compound) causes Neuropathy (Side Effect)